Inhibrx Biosciences, Inc. (INBX) Financial Statements
Inhibrx Biosciences, Inc. (INBX) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$138.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$131.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
INBXInhibrx Biosciences, Inc.Follow INBX — free
—
Price chart with a free account
- Market cap
- 1.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 13 Nov, in 20 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 0.2 | 1.3 | 0.0 | |
| Research & development | 203.7 | 113.0 | 103.0 | |
| Operating income | -331.4 | -135.0 | -127.8 | |
| Pre-tax income | 1,687.6 | -140.1 | -138.2 | |
| Income tax | 0.0 | 0.0 | 0.0 | |
| Net income | 1,687.6 | -140.1 | -138.2 | |
| Diluted EPS ($) | 112.62 | -9.04 | -8.88 | |
| Diluted shares (mn) | 15.0 | 15.5 | — |
USD millions · SEC XBRL
Inhibrx Biosciences, Inc. — questions
- What is Inhibrx Biosciences, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Inhibrx Biosciences, Inc.'s net income?
- -$138.2M over the twelve months to 2026-06-30.
- What is Inhibrx Biosciences, Inc.'s free cash flow?
- -$131.9M over the twelve months to 2026-06-30.
- What are Inhibrx Biosciences, Inc.'s diluted earnings per share?
- $-8.88 over the twelve months to 2026-06-30.
Every figure on this page comes from Inhibrx Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.